Illumina taps IBM Watson for cancer data interpretation

IBM Watson Health is now collaborating with Illumina, a biotechnology company focused on genome sequencing solutions.

Advertisement

Through this partnership, Illumina will integrate Watson for Genomics into its BaseSpace Sequence Hub and tumor sequencing process in an effort to standardize genomic data interpretation. Watson for Genomics will read genetic alteration files alongside professional guidelines, medical literature and clinical trials to produce a comprehensive report for researchers.

The Watson for Genomics and Illumina integration will take place in early 2017.

More articles on health IT:
US IoT Working Group: IoT personalizes care, reduces cost in healthcare
University of Dayton to establish center for ‘cyberhealth’
American Association for Cancer Research releases public cancer dataset with 19k records

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

What clinicians need from AI after the pilot: Lessons from Adventist Health and Rady Children’s

Friday, July 24
12:00 PM - 1:00 PM CDT

Presenters: Dr. Dieter Sumerauer, Rady Children’s HealthDr. Salman Naqvi, AdventistDr. Reid Conant, Abridge

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.